Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment

February 19, 2024
Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients …

News

Iovance’s Amtagvi gains FDA accelerated approval for melanoma treatment

February 19, 2024
Medical Communications Iovance, Oncology, accelerated approval, melanoma

Iovance Biotherapeutics has announced that the US Food and Drug Administration (FDA) has approved Amtagvi (lifileucel) suspension for intravenous infusion …

News

Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics

February 16, 2024
Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology

Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …

News

Freenome raises $254m funding for early cancer detection platform

February 16, 2024
Research and Development Diagnostics, Freenome, Oncology, cancer detection, funding

Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement …

News

Domainex opens new Biology Centre of Excellence in Cambridge, UK

February 14, 2024
Business Services Pharmacy, domainex, facility

Domainex has announced that it has opened a new Biology Centre of Excellence at the Unity Campus at Pampisford, Cambridge, …

News

FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment

February 14, 2024
Medical Communications FDA, Oncology, Onivyde, ipsen, pancreatic adenocarcinoma

Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for …

News

EC approves Vertex’s Casgevy for sickle cell disease treatment

February 13, 2024
Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease

Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …

News

DelSiTech and Tolmar announce global license and development agreement

February 13, 2024
Medical Communications DelSiTech, Pharmacy, Tolmar, collaboration

DelSiTech and Tolmar International have announced that they have entered into a global license and development agreement, following a previous …

News

J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment

February 12, 2024
Medical Communications Breakthrough Therapy Designation, FDA, HDFN, J&J, Reproductive health

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) …

News

GSK gains FDA Fast Track designation for chronic hepatitis B treatment

February 12, 2024
Medical Communications FDA, GSK, Hepatology, fast track designation, hepatitis B

GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational …

News

BioNTech and Autolus announce CAR T-cell therapy collaboration

February 9, 2024
Research and Development Autolus, BioNTech, CAR T-cell, Oncology, collaboration

BioNTech and Autolus Therapeutics have announced that they have entered a strategic collaboration intended to further both companies’ autologous CAR …

News

Fresenius Medical Care gains FDA 501(k) clearance for haemodialysis system

February 9, 2024
Medical Communications 501(k), FDA, Fresenius Medical Care, Nephrology, dialysis

Fresenius Medical Care has announced that it has received US Food and Drug Administration (FDA) 501(k) clearance for its 5008X …

News

Regenxbio announces positive data from trial for MPS II treatment

February 8, 2024
Research and Development Hunter syndrome, MPS II, Neurology, Regenxbio, clinical trial

Regenxbio has announced topline results from the phase 1/2/3 CAMPSIITE trial of RGX-121 for the treatment of patients up to …

News

Tenax Therapeutics enrolls first patient in phase 3 trial for pulmonary hypertension treatment

February 8, 2024
Research and Development Cardiology, Tenax Therapeutics, clinical trial, pulmonary hypertension

Tenax Therapeutics has announced that it has enrolled the first patient in its phase 3 LEVEL study, which aims to …

News
brano-mm1vipqd0oa-unsplash

Jazz Pharmaceuticals enters agreement to acquire rights to KRAS inhibitor programme from Redx Pharma

February 7, 2024
Business Services Pharmacy, RedX Pharma, acquisition, jazz pharmaceuticals

Jazz Pharmaceuticals and Redx Pharma have announced that the companies have signed a definitive agreement under which Jazz will acquire …

News

Medidata and Sanofi Vaccines extend collaboration

February 7, 2024
Research and Development Immunology, Medidata, Sanofi Vaccines, eCOA

Medidata and Sanofi Vaccines have announced a collaboration utilising Medidata electronic clinical outcome assessment (eCOA) within vaccine trials, building on …

News

Novartis to acquire MorphoSys AG for €2.7bn

February 6, 2024
Business Services Novartis, Pharmacy, acquisition, morphosys

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, or €68 per share. The …

News

Vertex announces positive results from trial for cystic fibrosis combination treatment

February 6, 2024
Research and Development Chronic Diseases, Vertex pharmaceuticals, clinical trial, combination treatment, cystic fibrosis

Vertex Pharmaceuticals has announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor programme, the company’s phase 3 programme for the treatment of …

News

Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets

February 5, 2024
Business Services Cialis, Eli Lilly, Pharmacy, Zuellig Pharma, acquisition

Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) and Alita (Pemetrexed) from Eli …

News

Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment

February 5, 2024
Medical Communications EMA, Oncology, Regeneron, linvoseltamab, multiple myeloma

Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorisation Application (MAA) for …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026